0000899243-18-016285.txt : 20180612
0000899243-18-016285.hdr.sgml : 20180612
20180612202630
ACCESSION NUMBER: 0000899243-18-016285
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180608
FILED AS OF DATE: 20180612
DATE AS OF CHANGE: 20180612
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lowrance David L
CENTRAL INDEX KEY: 0001408498
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-32157
FILM NUMBER: 18895675
MAIL ADDRESS:
STREET 1: 422 WILLIAM WALLACE DRIVE
CITY: FRANKLIN
STATE: TN
ZIP: 37064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Savara Inc
CENTRAL INDEX KEY: 0001160308
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841318182
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
BUSINESS PHONE: 512-614-1848
MAIL ADDRESS:
STREET 1: 900 S. CAPITAL OF TEXAS HIGHWAY
STREET 2: SUITE 150
CITY: AUSTIN
STATE: TX
ZIP: 78746
FORMER COMPANY:
FORMER CONFORMED NAME: Mast Therapeutics, Inc.
DATE OF NAME CHANGE: 20130312
FORMER COMPANY:
FORMER CONFORMED NAME: ADVENTRX PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20030613
FORMER COMPANY:
FORMER CONFORMED NAME: BIOKEYS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20010928
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-08
0
0001160308
Savara Inc
SVRA
0001408498
Lowrance David L
6836 BEE CAVE ROAD, BUILDING III
SUITE 200
AUSTIN
TX
78746
0
1
0
0
Chief Financial Officer
Common Stock
2018-06-08
4
S
0
675
12.1283
D
23080
D
Common Stock
2018-06-11
4
S
0
700
12.0516
D
22380
D
Common Stock
2018-06-12
4
S
0
3900
12.0781
D
18480
D
The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 29, 2017.
The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.40. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.2575. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
The price is a weighted average sale price. The sale prices ranged from $12.00 to $12.23. The reporting person undertakes to provide Savara Inc., any security holder of Savara Inc., or the staff of the Securities and Exchange Commission, upon receipt of a request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
/s/ David Lowrance
2018-06-12